Dyne Therapeutics has announced a significant investment in the Myotonic Dystrophy Clinical Research Network (DMCRN), which MDF helped launch and expand over the past 5 years, to include new sites across the UK and Europe. The DMCRN recently began recruiting for the largest longitudinal study of DM1 ever conducted, and Dyne’s support will enable expansion from 500 to 650 participants. Read more here.
Dyne also issued a press release on the results of a study of a potential antisense oligonucleotide therapy for DM1, FORCETM, in nonhuman primates. You can read the results of the study via the full press release here.
Check the Dyne Therapeutics website for more information and updates.